Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lundbeck

56.00 DKK+0.63 %6.11, 17.10
Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.63 %
+24.83 %
+34.87 %
+31.58 %
+29.75 %
+21.48 %
+52.26 %
+54.87 %
+127.64 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Read more
Market cap
55.76B DKK
Turnover
27.52M DKK
Revenue
24.63B
EBIT %
21.42 %
P/E
17.39
Dividend yield-%
2.05 %
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 04.09.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
11.11
2026

Interim report Q3'26

10.2
2027

Annual report '26

All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

HCA Morgenbørs 26/10 - Peter Garnry om SpaceX og positive Genmab-data
Video26.10.2026, 09.18
by Jacob Frehr, Michael Friis

HCA Morgenbørs 26/10 - Peter Garnry om SpaceX og positive Genmab-data

Udsigt til en svag positiv åbning i Europa fra morgenstunden, selv om Wall Street lukkede lavere fredag på stigende oliepriser. Efter lukketid i fredags meldte Genmab ud (positive fase 3-data i æggestokkræft). Gæst i studiet er Peter Garnry fra Gesda Capital, der vil tale om SpaceX.

GenmabVestas Wind SystemsBetter CollectiveNovonesisNovo NordiskSpaceXDSVLundbeck
HCA Morgenbørs 19/10 - Fokus på DSV i interview med Lars Hytting fra Aarthascope
Video19.10.2026, 09.18
by Michael Friis, Rasmus Køjborg

HCA Morgenbørs 19/10 - Fokus på DSV i interview med Lars Hytting fra Aarthascope

Udsigt til en svag negativ åbning i Europa fra morgenstunden efter uro i Frankrig. Fokus på bl.a.  Lundbeck (ændringer i bestyrelsen). Gæst i studiet her til morgen er Lars Hytting fra Aarthascope, der bl.a. vil tale om DSV.

Novo NordiskDSVGomSpaceLundbeckGenmabNKTEmbla MedicalColoplast
Dagens aktienyheder 19/10/2026: Lundbeck, Nordea, BioPorto og GreenMobility
Analyst Comment19.10.2026, 08.54
by Victor Skriver

Dagens aktienyheder 19/10/2026: Lundbeck, Nordea, BioPorto og GreenMobility

Lundbeck oplyste i går aftes, at bestyrelsesformanden træder tilbage ved generalforsamlingen i 2027. Efter Q3 2026 regnskabet fra Nordea torsdag udgav vores finske kollegaer i Inderes en opdateret analyse på banken om fredagen. På BioPortos investormøde den 7. oktober gav professor dr. Jun Oh fra Heidelberg University Hospital et uafhængigt klinisk perspektiv på, hvad de opdaterede KDIGO-retningslinjer betyder for NGAL. GreenMobility har her til morgen meddelt, at selskabet har indgået en samarbejdsaftale med OBI Media.

LundbeckNordeaBioPortoGreenMobility

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release18.10.2026, 17.54

Changes to the Board of Directors of H. Lundbeck A/S

Lundbeck
Lundbeck - Præsentation af delårsrapport for Q3 2026
Webcast12.11.2026, 13.00

Lundbeck - Præsentation af delårsrapport for Q3 2026

H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.

Lundbeck
Press release06.10.2026, 08.00

H. Lundbeck A/S: Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

Lundbeck
Press release02.10.2026, 08.00

H. Lundbeck A/S: Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

Lundbeck
Dagens aktienyheder 01/10/2026: Gubra og Lundbeck
Analyst Comment01.10.2026, 08.50
by Victor Skriver

Dagens aktienyheder 01/10/2026: Gubra og Lundbeck

Dagens aktienyheder 01/10/2026: Gubra og Lundbeck

GubraLundbeck
Press release01.10.2026, 08.00

H. Lundbeck A/S: Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Lundbeck
Regulatory press release28.09.2026, 08.25

H. Lundbeck A/S: Lars Bang, Executive Vice President, Product Development & Supply, has passed away

Lundbeck
Analyst Comment25.09.2026, 09.04
by Rasmus Køjborg, Michael Friis

Today's equity news 25/09/2026: Lundbeck, Sampo, and North Media

Today's equity news 09/25/2026: Lundbeck, Sampo and North Media

LundbeckSampoNorth Media
Press release25.09.2026, 08.00

H. Lundbeck A/S: Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters

Lundbeck
Regulatory press release21.09.2026, 16.20

Correction - Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck
Regulatory press release17.09.2026, 08.53

H. Lundbeck A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

Lundbeck
Dagens aktienyheder 16/09/2026: Hafnia, Torm, Lundbeck og Scandinavian Medical Solutions
Analyst Comment16.09.2026, 08.50
by Victor Skriver

Dagens aktienyheder 16/09/2026: Hafnia, Torm, Lundbeck og Scandinavian Medical Solutions

Dagens aktienyheder 16/09/2026: Hafnia, Torm, Lundbeck og Scandinavian Medical Solutions

TormHafniaLundbeckScandinavian Medical Solutions
Press release16.09.2026, 08.00

H. Lundbeck A/S: Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

Lundbeck
Press release15.09.2026, 09.00

H. Lundbeck A/S: Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Lundbeck
Dagens aktienyheder 14/09/2026: Lundbeck og Danish Aerospace and Defence Company
Analyst Comment14.09.2026, 08.54
by Victor Skriver

Dagens aktienyheder 14/09/2026: Lundbeck og Danish Aerospace and Defence Company

Dagens aktienyheder 14/09/2026: Lundbeck og Danish Aerospace and Defence Company

LundbeckDanish Aerospace and Defence Company
Press release11.09.2026, 10.00

H. Lundbeck A/S: The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome

Lundbeck
HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport
Video10.09.2026, 10.55
by Michael Friis, Nikolaj Pedersen

HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport

Europæiske futures indikerer en begrænset positiv åbning efter gårsdagens nedtur, forud for fredagens afgørende inflationsrapport. Herhjemme fokus på blandt andet Mærsk, Novo, NTG, B&O.

Bang & OlufsenLundbeckNovo NordiskDSVA.P. Møller - MærskNTG Nordic Transport Group